Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis

Medicine (United States)

Volumn 96, Issue 16, 2017, Pages

  Uygun, Ahmet ^a   Ozturk, Kadir ^a   Demirci, Hakan ^a   Oger, Cem ^a   Avci, Ismail Yasar ^b   Turker, Turker ^a   Gulsen, Mustafa ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Turkey)

^b Microbiology Department   (Turkey)

Author keywords

Fecal transplantation; Intestinal microbiata; Ulcerative colitis

Indexed keywords

ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLONOSCOPY; DIARRHEA; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NAUSEA; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; STEROID THERAPY; TREATMENT RESPONSE; ULCERATIVE COLITIS; VOMITING; ADVERSE EFFECTS; COLITIS, ULCERATIVE; DIAGNOSTIC IMAGING; MIDDLE AGED; RETREATMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLONOSCOPY; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESALAMINE; MIDDLE AGED; RETREATMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85018269465     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006479     Document Type: Article

References (26)

1. Loftus EVJr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
2. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;146:1489-99.
3. Serban DE. Microbiota in inflammatory bowel disease pathogenesis and therapy: is it all about diet? Nutr Clin Pract 2015;30:760-79.
4. Danese S, Fiocchi C. Ulcerative colitis. NEngl J Med 2011;365:1713-25.
5. Girotra M, Garg S, Anand R, et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection in the elderly: long-term outcomes and microbiota changes. Dig Dis Sci 2016;61:3007-15.
6. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2014;8:1569-81.
7. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102-9.
8. Paramsothy S, Kamm M, Walsh A, et al. Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial. J Crohns Colitis 2016;10:S14.
9. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015;149:110-8.
10. SilverbergMS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5A-36A.
11. Cammarota G, Pecere S, Ianiro G, et al. Principles of DNA-based gut microbiota assessment and therapeutic efficacy of fecal microbiota transplantation in gastrointestinal diseases. Dig Dis 2016;34:279-85.
12. Kump PK, Gröchenig HP, Lackner S, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013;19:2155-65.
13. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 2014;146:1547-53.
14. Sun D, Li W, Li S, et al. Fecal microbiota transplantation as a novel therapy for ulcerative colitis: a systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e3765.
15. Shi Y, Dong Y, Huang W, et al. Fecal microbiota transplantation for ulcerative colitis: a systematic review and meta-analysis. PLoS One 2016;11:e0157259.
16. Cui B, Li P, Xu L, et al. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med 2015;13:298.
17. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review andmeta-analysis. Am J Gastroenterol 2013;108:500-8.
18. Scaldaferri F, Pecere S, Petito V, et al. Efficacy and mechanisms of action of fecal microbiota transplantation in ulcerative colitis: pitfalls and promises from a first meta-analysis. Transplant Proc 2016;48: 402-7.
19. Kump P, Högenauer C. Any future for fecal microbiota transplantation as treatment strategy for inflammatory bowel diseases? Dig Dis 2016;34 (Suppl 1):74-81.
20. Xu L, Zhang T, Cui B, et al. Clinical efficacy maintains patients' positive attitudes toward fecal microbiota transplantation. Medicine (Baltimore) 2016;95:e4055.
21. DammanCJ, BrittnacherMJ, WesterhoffM, et al.Lowlevel engraftment and improvement following a single colonoscopic administration of fecal microbiotato patients with ulcerative colitis. PLoS One 2015;10:e0133925.
22. Kahn SA, Vachon A, Rodriquez D, et al. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis 2013;19:1506-13.
23. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329-42.
24. Zhang T, Cui B, Li P, et al. Short-term surveillance of cytokines and C-reactive protein cannot predict efficacy of fecal microbiota transplantation for ulcerative colitis. PLoS One 2016;11:e0158227.
25. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63:88-95.
26. Reinisch W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012;35:568-76.